Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Three-Arm Study to Evaluate the Effects of 3-Week Supplementation With Single (THRIVE4U(TM) TG Lipase) and Combination Lipase (THRIVE4U(TM) Spectrum Lipases) Products on Increasing Fatty Acid Absorption in Generally Healthy Adults With Potential Exocrine Pancreatic Dysfunction
NCT07893288 is registered in ClinicalTrials.gov with Danisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Three-Arm Study to Evaluate the Effects of 3-Week Supplementation With Single (THRIVE4U(TM) TG Lipase) and Combination Lipase (THRIVE4U(TM) Spectrum Lipases) Products on Increasing Fatty Acid Absorption in Generally Healthy Adults With Potential Exocrine Pancreatic Dysfunction
- Lead sponsor
- Danisco
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2026
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
digestive symptoms, gastrointestinal symptoms, healthy, impaired pancreatic function
Arms
As registered; 3 arms.
-
THRIVE4U™ TG Lipase (TP1)
Study product dosing sequences: Dose Level 1(Low) → Dose Level 2 (Medium) → Dose Level 3 (High)
-
THRIVE4U™ Spectrum Lipases (TP2)
Study product dosing sequences: Dose Level 1(Low) → Dose Level 2 (Medium) → Dose Level 3 (High)
-
Placebo
Same dose throughout
Primary endpoints
Registered primary outcome measures; 6 primary.
-
To evaluate the dose-response effect of THRIVE4U™ TG Lipase (TP1) and THRIVE4U™ Spectrum Lipases (TP2) on increasing fatty acid absorption across ascending dose levels within each TP group after a single dose
Plasma concentrations EPA as assessed by the O3-SACT
-
To evaluate the dose-response effect of TP1 and TP2 on increasing fatty acid absorption across ascending dose levels within each TP group after a single dose
Plasma concentrations DHA as assessed by the O3-SACT
-
To evaluate the dose-response effect of TP1 and TP2 on increasing fatty acid absorption across ascending dose levels within each TP group after a single dose
Plasma concentrations total fatty acid profile as assessed by the O3-SACT
-
To evaluate the effects TP1 and TP2 on increasing fatty acid absorption at different dose levels compared to placebo after a single dose
Plasma concentrations of EPA as assessed by the O3-SACT
-
To evaluate the effects TP1 and TP2 on increasing fatty acid absorption at different dose levels compared to placebo after a single dose
Plasma concentrations of DHA as assessed by the O3-SACT
+1 more primary endpoint
Lead sponsor's other trials
Danisco, most recent start first.
+18 more trials See the organization page